Videos Only
Overview
Scottsdale Interventional Forum (SIF) 2025 This symposium is designed to equip participants with the practical skills needed to enhance bedside patient management, apply innovative therapies effectively, and improve outcomes for patients with cardiovascular disease.
Target Audience
This activity is intended for physicians, nurses, and allied health professionals seeking a comprehensive, up-to-date review of disease mechanisms, diagnostic imaging, and expert management strategies for advanced cardiovascular disorders.
Learning Objectives
By the end of this activity, participants should be able to:
- Explain the role of mechanical circulatory support in patients undergoing complex coronary intervention.
- Discuss novel stent platforms and the regulatory pathway to FDA approval.
- Develop a practical understanding of newer methods for plaque and calcium modification in coronary disease management.
- Compare surgical and percutaneous revascularization approaches in diabetic patients with complex coronary anatomy.
- Discuss the role of advanced imaging in cardiovascular disease management, including noninvasive imaging and high-resolution invasive coronary imaging such as OCT and IVUS.
- Describe the emerging role of mechanical left atrial appendage therapy, novel cerebral embolic protection devices, and adjunctive devices in structural heart disease management.
- Apply knowledge of radial-based and alternative vascular access approaches in cardiovascular therapy.
- Define the role of transcatheter and surgical therapies for patients with advanced aortic stenosis and aortic insufficiency.
- Discuss the role of transcatheter aortic valve replacement (TAVR) in patients with symptomatic moderate aortic stenosis.
- Describe catheter-based therapies for degenerative and functional mitral valve disease.
- Define emerging therapies for tricuspid and pulmonic valve disease.
- Review the most relevant clinical trials in coronary and structural heart disease that are shaping the near future of patient management.
- Review the most important recent trials in antiplatelet and antithrombotic therapy.
| S. No. | Title | Run Time |
|---|---|---|
| 1 | RCA ISR Management: Stent Boost and IVUS Inform DES Over DCB in Elderly Patient | 43:51 |
| 2 | Severe Valvular and Left Main CAD in Frail Patient: DK Crush PCI Strategy and Impella Support | 43:52 |
| 3 | Aortic Valve-in-Valve in Lotus Prosthesis: Technical Challenges and Key Lessons | 53:48 |
| 4 | Chronic Total Occlusion in RCA With Severe Obesity: Retrograde PCI Strategy and IVUS Guidance | 36:34 |
| 5 | Valve-in-Valve in Bicuspid AVR With Dacron Graft: Managing Fracture Limitations | 22:59 |
| 6 | CTO in RCA With Persistent Angina: Dual Guide Approach, IVUS Imaging, and Stenting | 39:37 |
| 7 | Presentation of a Case: Concomitant AF Ablation and LAA Occlusion | 36:38 |
| 8 | Severe MR in a 71-Year-Old: Valve-in-Valve-in-Ring Approach and Deployment Challenges | 15:07 |
| 9 | Women’s Heart Disease: Key Symptom Patterns and Early Detection | 07:51 |
| 10 | Examples of Escalating MCS in STEMI | 10:35 |
| 11 | Mechanical Complications of MI with Cardiogenic Shock: MitraClip Rescue | 08:58 |
| 12 | Vascular Access Challenges with MCS | 10:00 |
| 13 | Cut, Laser, Drill, and Shock | 15:28 |
| 14 | Massive Coronary Thrombosis- Treatment Algorithm and Creative Approaches | 16:18 |
| 15 | The Most Difficult Bifurcations- A Step-by-Step Algorithm | 15:32 |
| 16 | Approaches to Treating Complex Vein Graft Lesions (and the Native Vessels They Supply) | 14:57 |
| 17 | Mitral Transcatheter Edge-to-Edge Repair and Mandatory Mechanical Circulatory Support in Patients with Structural Shock | 13:19 |
| 18 | Novel Use of MitraClip to Treat Aortic Regurgitation | 08:52 |
| 19 | Intravascular Imaging is Now Class 1A in the European Guidelines: How Should US Interventionalists Respond? | 22:43 |
| 20 | Leaflet and Septal Modification during VIV TMVR: Rationale, Tips, and Tricks | 15:28 |
| 21 | Patient Selectiong for Tricuspid Therapies | 09:35 |
| 22 | Optimal TEE and 3D-ICE for Efficient and Effective T-TEER and TTVR | 11:00 |
| 23 | Transcatheter Mitral and Tricuspid Valve in Valve Best Practices | 10:57 |
| 24 | The Next Pillar of Heart Failure Management – the GLP-1 Agonist Phenomenon | 13:51 |
| 25 | Aortic Stenosis and Coronary Artery Disease: A Case Presentation | 11:07 |
| 26 | Coronary Evaluation and Stenting Pre-TAVR: Neither Cath nor PCI Frequently Necessary | 08:37 |
| 27 | Echo Gradients Are Flawed: All BE and SE Valves Do Well! | 08:26 |
| 28 | The Transcatheter Valve Journey: Present and Future | 12:56 |
| 29 | TAV-in-SAV and TAV-in-TAV: ABCDs of the Pre-Procedural Evaluation | 13:01 |
| 30 | Pre TAVR: Cath and Aggressive PCI for All? | 11:59 |
| 31 | The Data Are Clear: Self-Expanding Superior in Smaller Valves | 11:35 |
| 32 | Catheter Based Treatment for Valvular Heart Disease | 03:44 |
| 33 | Advances in Coronary Artery Disease Management | 07:28 |
| 34 | The Growing Field of Heart Failure Management | 10:49 |
| 35 | EVOQUE Tricuspid Valve Replacement | 10:38 |
| 36 | Strategies to Prevent Heart Disease | 05:45 |
| 37 | Managing Stable CAD in Severe Aortic Stenosis: Insights from NOTION and PCI Strategies | 12:04 |
| 38 | Mean Gradient with TEER: Why Higher Gradients Should be Tolerated | 10:37 |
| 39 | Optimal Pharmacologic Management Following LAAO | 09:29 |
| 40 | Left Atrial Appendage Occlusion: Current Advances, Remaining Challenges | 10:15 |
| 41 | M-TEER for Functional MR | 13:59 |
| 42 | Putting LAAO Clinical Trials in Perspective | 10:34 |
| 43 | How to Treat This 75-Year-Old with Severe Degenerative MR | 02:10 |
| 44 | Catheter-Based Therapies for Managing Aortic Insufficiencies | 22:27 |
| 45 | Spare the Blade – M-TEER Today! | 04:50 |
| 46 | The Data Are Favorable, but Can T-TEER Be Democratized? | 12:37 |
| 47 | Mitral Debate – No Way – Surgical Repair Rules Today! | 11:58 |
| 48 | Understanding FDA T-TEER Trials: Are There Enough Pros? | 16:03 |
| 49 | The Role of Transcatheter Tricuspid Valve Replacement: Unsuccessful TTEER with Giant Coaptaion Gap | 10:27 |
| 50 | CT Guidance in TMVR: Lessons Learned and Evolving Imaging Protocols | 13:14 |
| 51 | Tricuspid Regurgitation Impact on TAVR and M-TEER | 10:35 |
| 52 | Transcatheter Repair versus Mitral Valve Surgery for Secondary Mitral Regurgitation – Challenges in Trial Design and Interpretation of Outcomes | 10:00 |
| 53 | Should There Be Sex-Based Considerations in the Care of the AS Patient? | 13:11 |
| 54 | Will T-TEER Evolve Similar to M-TEER: an Operator’s Perpsective | 11:27 |
| 55 | Upstream Treatment of AS: Early TAVR, Evolved, TAVR Unload | 19:37 |
| 56 | Back to the Basics: Are Exercise Right Heart Catheterizations Mandatory? | 05:37 |
| 57 | CVD Jeopardy: Cath Lab & ICU Essentials – Arrhythmias, Shock, and Dissection Anticoagulation Pitfalls | 17:30 |
| 58 | The Evolution of HFrEF Therapies | 13:52 |
| 59 | The Emerging Role of Transcatheter Shunts | 10:01 |
| 60 | Evidence-Based Interventions Targeting Valvular Heart Disease in Heart Failure | 15:13 |
| 61 | ModulHeart, Aortix and the Novel Support Devices for Heart Management | 15:08 |
| 62 | Mea Culpa, Mea Culpa, Mea Maxima Culpa – STEMI Management | 13:11 |
| 63 | Left Atrial–Coronary Sinus Shunt Case: Salvaging a Disaster | 11:50 |
| 64 | The Heartbreak of Substance Use | 15:23 |
| 65 | Contemporary Management of STEMI/SHOCK | 14:35 |
| 66 | Cardiac Biomarkers in Acute and Chronic Care | 13:17 |
| 67 | Spontaneous Coronary Artery Dissection: Women & Heart Disease | 14:18 |
| 68 | Equipoise – What’s That – We Did That Study Already | 11:07 |
| 69 | Structural Heart Disease – Evaluation, Management and Postop Care | 15:11 |
| 70 | Transcatheter Repair versus Mitral Valve Surgery for Secondary Mitral Regurgitation | VIDEO |
| 71 | Cryptogenic Stroke: What’s a PFO? | 08:37 |
| 72 | Surgical vs Transcatheter Approaches in Functional Mitral Regurgitation: Short and Long-Term Data | 06:25 |
| 73 | Failure to Cross: Success Begins with Failure | 15:16 |
| 74 | Left Main Disease: Management Challenges and PCI vs CABG Decision-Making | 10:22 |
| 75 | Making the Cath Lab a Safer Environment: Advances in Radiation Safety | 12:55 |
| 76 | Top Coronary Trials of the Last Year – 2025 Update | 14:09 |
| 77 | Oh, How I Wish That Wouldn’t Have Happened | 19:03 |
| 78 | Will There Be New Indications for the Use of DCB in Coronary Intervention? | 13:22 |
| 79 | CCTA in 2025 – Planning PCI | 11:26 |
| 80 | AMI With Cardiogenic Shock and RV Failure: Escalating to ECMO for Hemodynamic Rescue | 02:55 |
| 81 | Comprehensive Invasive Physiology Suite: From Diagnosis to Outcomes | 10:20 |
| 82 | STEMI vs. Cardiogenic Shock: Understanding the Data on Complete vs. Culprit-Only PCI | 13:07 |
| 83 | Expanding Indication for Intravascular Lithotripsy | 14:50 |
| 84 | Restore EF, Protect III, Protect IV: Where Is the Data Leading? | 09:00 |
| 85 | Shock Outcomes in 2024: Review of Recent Data and Where to Go from There | 14:45 |
| 86 | Acute Cardiogenic Shock Management | 10:17 |
| 87 | STEMI Management: Unloading Before Revascularization – Clinical Implications | 10:53 |
| 88 | Elective Multivessel CAD and the Evidence for Complete Revascularization | 09:50 |




